175 related articles for article (PubMed ID: 34248926)
1. A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.
Lin J; Wang X; Zhang C; Bu S; Zhao C; Wang H
Front Immunol; 2021; 12():606027. PubMed ID: 34248926
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC.
Liu M; Xia S; Zhang X; Zhang B; Yan L; Yang M; Ren Y; Guo H; Zhao J
Lung Cancer; 2022 Aug; 170():148-155. PubMed ID: 35792434
[TBL] [Abstract][Full Text] [Related]
3. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
[TBL] [Abstract][Full Text] [Related]
4. A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab.
Shang X; Shi J; Wang X; Zhao C; Yu H; Wang H
Cancer Med; 2021 Sep; 10(18):6218-6226. PubMed ID: 34331414
[TBL] [Abstract][Full Text] [Related]
5. Non-small-cell lung cancer patients harboring
Zhang C; Wang K; Lin J; Wang H
Future Oncol; 2022 Sep; 18(27):3031-3041. PubMed ID: 36065989
[TBL] [Abstract][Full Text] [Related]
6. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
Wang H; Shan Q; Guo J; Han X; Zhao C; Li H; Wang Z
Lung Cancer; 2021 Jan; 151():76-83. PubMed ID: 33246647
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring
Nie W; Gan L; Wang X; Gu K; Qian FF; Hu MJ; Zhang D; Chen SQ; Lu J; Cao SH; Li JW; Wang Y; Zhang B; Wang SY; Li CH; Yang P; Xu MD; Zhang XY; Zhong H; Han BH
Oncoimmunology; 2021 Jan; 10(1):1865670. PubMed ID: 33537171
[TBL] [Abstract][Full Text] [Related]
8. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies.
Qian J; Nie W; Lu J; Zhang L; Zhang Y; Zhang B; Wang S; Hu M; Xu J; Lou Y; Dong Y; Niu Y; Yan B; Zhong R; Zhang W; Chu T; Zhong H; Han B
Int J Cancer; 2020 Jun; 146(11):3124-3133. PubMed ID: 31583695
[TBL] [Abstract][Full Text] [Related]
9. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.
Ramagopalan S; Gupta A; Arora P; Thorlund K; Ray J; Subbiah V
JAMA Netw Open; 2021 Nov; 4(11):e2134299. PubMed ID: 34767024
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
12. Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials.
Zhou JG; Wong AH; Wang H; Jin SH; Tan F; Chen YZ; He SS; Shen G; Frey B; Fietkau R; Hecht M; Carr SR; Wang R; Shen B; Schrump DS; Ma H; Gaipl US
Front Immunol; 2022; 13():961926. PubMed ID: 36119066
[TBL] [Abstract][Full Text] [Related]
13. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Fehrenbacher L; von Pawel J; Park K; Rittmeyer A; Gandara DR; Ponce Aix S; Han JY; Gadgeel SM; Hida T; Cortinovis DL; Cobo M; Kowalski DM; De Marinis F; Gandhi M; Danner B; Matheny C; Kowanetz M; He P; Felizzi F; Patel H; Sandler A; Ballinger M; Barlesi F
J Thorac Oncol; 2018 Aug; 13(8):1156-1170. PubMed ID: 29777823
[TBL] [Abstract][Full Text] [Related]
14. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ
Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials.
Mazieres J; Rittmeyer A; Gadgeel S; Hida T; Gandara DR; Cortinovis DL; Barlesi F; Yu W; Matheny C; Ballinger M; Park K
J Thorac Oncol; 2021 Jan; 16(1):140-150. PubMed ID: 33166718
[TBL] [Abstract][Full Text] [Related]
16. ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.
Zou W; Yaung SJ; Fuhlbrück F; Ballinger M; Peters E; Palma JF; Shames DS; Gandara D; Jiang Y; Patil NS
JCO Precis Oncol; 2021 Nov; 5():827-838. PubMed ID: 34994614
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
18. A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab.
Nie W; Qian J; Xu MD; Gu K; Qian FF; Hu MJ; Lu J; Gan L; Zhang XY; Cao SH; Li JW; Wang Y; Zhang B; Wang SY; Hu F; Li CH; Zhong H; Han BH
Oncoimmunology; 2020; 9(1):1731072. PubMed ID: 32158623
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study.
Hida T; Kaji R; Satouchi M; Ikeda N; Horiike A; Nokihara H; Seto T; Kawakami T; Nakagawa S; Kubo T
Clin Lung Cancer; 2018 Jul; 19(4):e405-e415. PubMed ID: 29525239
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Herbst RS; Giaccone G; de Marinis F; Reinmuth N; Vergnenegre A; Barrios CH; Morise M; Felip E; Andric Z; Geater S; Özgüroğlu M; Zou W; Sandler A; Enquist I; Komatsubara K; Deng Y; Kuriki H; Wen X; McCleland M; Mocci S; Jassem J; Spigel DR
N Engl J Med; 2020 Oct; 383(14):1328-1339. PubMed ID: 32997907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
